Fibrosis rescue improves cardiac function in dystrophin-deficient mice and Duchenne patient-specific cardiomyocytes by immunoproteasome modulation
Altro
Data di Pubblicazione:
2019
Citazione:
Fibrosis rescue improves cardiac function in dystrophin-deficient mice and Duchenne patient-specific cardiomyocytes by immunoproteasome modulation / P. Bella, A. Farini, A. Gowran, C. Villa, C. Sitzia, A. Scopece, G. Pompilio, G.P. Comi, F. Fortunato, Y. Torrente. ((Intervento presentato al 6. convegno International Congress of Myology tenutosi a Bordeaux nel 2019.
Abstract:
Patients affected by Duchenne Muscular Dystrophy (DMD) develop a progressive dilated cardiomyopathy characterized by inflammatory cell infiltration, necrosis and cardiac fibrosis. Standard treatments consider the use of β‐blockers and angiotensin‐converting enzyme inhibitors that are symptomatic and unspecific towards DMD disease. Medications that target DMD cardiac fibrosis are in early stages of development. Here, we demonstrated immunoproteasome dysregulation in affected hearts of mdx mice (murine animal model of DMD) and cardiomyocytes derived from induced pluripotent stem cells of DMD patients. More interestingly, immunoproteasome inhibition ameliorated cardiomyopathy in mdx mice and reduced the development of cardiac fibrosis. Establishing the immunoproteasome inhibition dependent cardioprotective role suggests the possibility to modulate the immunoproteasome as novel and clinically relevant treatment to rescue dilated cardiomyopathy in DMD patients.
Tipologia IRIS:
14 - Intervento a convegno non pubblicato
Elenco autori:
P. Bella, A. Farini, A. Gowran, C. Villa, C. Sitzia, A. Scopece, G. Pompilio, G.P. Comi, F. Fortunato, Y. Torrente
Link alla scheda completa: